Birgitta Versluijs

103 Good outcome of untreated RSV in pediatric HCT 1. Chemaly RF, Shah DP, Boeckh MJ. Ma- nagement of respiratory viral infections in hematopoietic cell transplant reci- pients and patients with hematologic malignancies. Clin Infect Dis 2014; 59 Suppl 5: S344-51. 2. Shah DP, Ghantoji SS, Shah JN, et al. Impact of aerosolized ribavirin on mor- tality in 280 allogeneic haematopoie- tic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother 2013; 68(8): 1872-80. 3. Waghmare A, Englund JA, Boeckh M. How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation. Blood 2016; 127(22): 2682-92. 4. Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth European Conference on Infec- tions in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluen- za virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis 2013; 56(2): 258-66. 5. Versluys AB, van der Ent K, Boelens JJ, Wolfs T, de Jong P, Bierings MB. High Diagnostic Yield of Dedicated Pulmona- ry Screening before Hematopoietic Cell Transplantation in Children. Biol Blood Marrow Transplant 2015; 21(9): 1622-6. 6. Versluys AB, Rossen JW, van Ewijk B, Schuurman R, Bierings MB, Boelens JJ. Strong association between respiratory viral infection early after hematopoietic stem cell transplantation and the deve- lopment of life-threatening acute and chronic alloimmune lung syndromes. Biol Blood Marrow Transplant 2010; 16(6): 782-91. 7. Shah DP, Ghantoji SS, Ariza-Heredia EJ, et al. Immunodeficiency scoring index to predict poor outcomes in hemato- poietic cell transplant recipients with RSV infections. Blood 2014; 123(21): 3263-8. 8. Shah DP, Ghantoji SS, Mulanovich VE, Ariza-Heredia EJ, Chemaly RF. Manage- ment of respiratory viral infections in hematopoietic cell transplant recipients. Am J Blood Res 2012; 2(4): 203-18. 9. Robinson JL, Grenier D, MacLusky I, Al- len UD. Respiratory syncytial virus infec- tions in pediatric transplant recipients: A Canadian Paediatric Surveillance Pro- gram study. Pediatr Transplant 2015; 19(6): 659-62. 10. Kim YJ, Guthrie KA, Waghmare A, et al. Respiratory syncytial virus in hemato- poietic cell transplant recipients: factors determining progression to lower res- piratory tract disease. J Infect Dis 2014; 209(8): 1195-204. 11. Renaud C, Xie H, Seo S, et al. Mortality rates of human metapneumovirus and respiratory syncytial virus lower respi- ratory tract infections in hematopoie- tic cell transplantation recipients. Biol Blood Marrow Transplant 2013; 19(8): 1220-6. 12. Chávez-Bueno S, Mejías A, Merryman RA, Ahmad N, Jafri HS, Ramilo O. Intra- venous palivizumab and ribavirin com- bination for respiratory syncytial virus disease in high-risk pediatric patients. Pediatr Infect Dis J 2007; 26(12): 1089- 93. 13. Molinos-Quintana A, Pérez-de Soto C, Gómez-Rosa M, Pérez-Simón JA, Pérez- Hurtado JM. Intravenous ribavirin for respiratory syncytial viral infections in pediatric hematopoietic SCT recipients. Bone Marrow Transplant 2013; 48(2): 265-8. 14. Waghmare A, Campbell AP, Xie H, et al. Respiratory syncytial virus lower respira- References 6